Institute for Hematology and Oncology, Klinikum rechts der Isar der Technischen Universität München, Munich, Germany.
Cytotechnology. 2002 Jan;38(1-3):155-64. doi: 10.1023/A:1021103723325.
Tumor-reactive CD4(+) T helper (Th) cells play a criticalrole in antitumor immunity, due to their ability to induceCD8(+) T cell-mediated cytotoxic activity and humoralresponse. This study focuses on the in vitro generationand expansion of Th cells specific for the tumor-associatedantigen ;human epidermal growth factor receptor-2' (HER2). Aprotocol for efficient HER2 presentation was developed usingautologous monocyte-derived dendritic cells (DC) as antigenpresenting cells (APC) and purified HER2 protein as antigensource. Our data suggest that DC pulsed with recombinantprotein of the extracellular domain (ECD) of HER2 (ECD/HER2)induce an ECD/HER2-specific Th cell response. This finding mayfacilitate the development of immunotherapy regimens withoutrequiring defined immunogenic epitopes of the antigen.
肿瘤反应性 CD4(+) T 辅助 (Th) 细胞在抗肿瘤免疫中发挥着关键作用，因为它们能够诱导 CD8(+) T 细胞介导的细胞毒性活性和体液反应。本研究专注于体外生成和扩增针对肿瘤相关抗原的 Th 细胞，即人类表皮生长因子受体-2' (HER2)。本研究使用自体单核细胞衍生的树突状细胞 (DC) 作为抗原呈递细胞 (APC)，并使用纯化的 HER2 蛋白作为抗原来源，开发了一种有效呈递 HER2 的方案。我们的数据表明，用重组 HER2 细胞外结构域 (ECD) 蛋白脉冲处理的树突状细胞 (ECD/HER2) 可诱导 ECD/HER2 特异性 Th 细胞反应。这一发现可能有助于开发免疫治疗方案，而无需使用抗原的明确免疫原性表位。
